Trial record 20 of 57 for:    "Anaplastic oligoastrocytoma"

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01339039
Recruitment Status : Terminated (Low accrual rate)
First Posted : April 20, 2011
Last Update Posted : November 17, 2017
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Massachusetts General Hospital
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Patrick Y. Wen, MD, Dana-Farber/Brigham and Women's Cancer Center

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Primary Completion Date : April 2014
  Study Completion Date : April 8, 2017